IMMUNIC, INC.
No enriched coverage for $IMUX in the last 7 days.
No SEC Form 4 filings for $IMUX in the last 30 days.
See all $IMUX insider activity →Immunic (IMUX) granted director Robert Thorvald Nagel 25,370 stock options at $10.12 per share. The options vest monthly over one year and expire in 2036. The economic benefits will be transferred to BVF Partners L.P.
Immunic, Inc. (IMUX) announced Dr. Duane Nash's resignation from its Board of Directors, reducing the board size to nine members. The company stated the resignation was not due to any disagreement. The change does not indicate any strategic, operational, or financial disruption, according to the filing.
IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Resignation of Director On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (
Recent IMUX coverage spans financial news, corporate actions and technology.
Small insider option grant with no immediate price impact.
Board seat reduction with no operational impact; likely neutral to price.
Board change may affect governance perception and short‑term stock volatility.
The filing signals continued development of the vidofludimus calcium candidate, which may affect the stock as investors assess trial timing and funding needs.
Significant capital raise provides runway and may boost valuation.
AlphAI scores every news story that mentions IMUX with an AI model for sentiment and relevance, and aggregates insider trades from IMMUNIC, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immunic (IMUX) granted director Robert Thorvald Nagel 25,370 stock options at $10.12 per share. The options vest monthly over one year and expire in 2036. The economic benefits will be transferred to BVF Partners L.P.
1 min readImmunic, Inc. (IMUX) announced Dr. Duane Nash's resignation from its Board of Directors, reducing the board size to nine members. The company stated the resignation was not due to any disagreement. The change does not indicate any strategic, operational, or financial disruption, according to the filing.
1 min readIMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Resignation of Director On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (
1 min readImmunic (IMUX) held an RMS R&D Day webinar on Sept. 9, 2026, presenting its vidofludimus calcium development plans. The company shared forward-looking statements on clinical development and potential phase 3 progression. Immunic cautioned about risks including trial timing and regulatory outcomes.
1 min readImmunic Inc. (IMUX) announced a private placement deal that could raise up to $400 million, with $200 million upfront. The funds will support clinical studies, operations, and future product launches. The stock surged 33% in premarket trading. The company plans to transition to a commercial-stage company and expects funds to last through 2027.
2 min readImmunic, Inc. (IMUX) will host a virtual R&D day on September 9, 2026, to discuss its Phase 3 ENSURE trials for vidofludimus calcium, an oral therapy for relapsing multiple sclerosis. The company expects top-line data by the end of 2026. Key opinion leaders will share insights on MS treatment and unmet medical needs.
1 min readAnalysts reiterated Buy ratings on Immunic (IMUX) with a $29 target, Incyte (INCY) with a $150 target, and Eli Lilly (LLY) with a $1600 target. Consensus targets suggest 167.5%, 6.6%, and 19.1% upside respectively.
2 min readImmunic AG (IMUX) appointed Chitrang Davé as Chief Data and Digital Officer. Davé will lead data systems, analytics, and digital strategy, supporting NDA submission and commercialization of vidofludimus calcium (IMU-838) for multiple sclerosis. He received an option to purchase 120,000 shares.
2 min readUS stocks ended lower as US-Iran talks remained unresolved amid Strait of Hormuz uncertainty. The Nasdaq fell 0.6% to 26,445, while the Dow and S&P 500 each declined 0.3%. Oil was steady near $82.50/bbl, according to IG’s Axel Rudolph. The article also cites company-specific moves including Nvidia’s $500B AI financing plan and several earnings, bids, and guidance updates.
7 min readImmunic Inc (NASDAQ:IMUX) said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium for relapsing multiple sclerosis remain on track for top-line data by year-end 2026. If positive, it plans a US NDA mid-2027 and a decision in 2028. Q2 operating expenses were $35.3M; net loss about $34.1M. Cash was $155.1M.
4 min read
